KDM6A and Patent ductus arteriosus: Yet, studies using genetically engineered mouse (GEM) models indicate that Kdm6a suppresses PDA progression through a demethylase-independent mechanism, raising the possibility that other KDM members may mediate hypoxia-driven reprogramming of the malignant state26.